Strive Health, a Denver, CO-based value-based kidney care company, secured a $140m Series B funding round.
The round, which brought total funding to $223.5m, was led by CapitalG, with participation from Redpoint and current investors NEA, Town Hall Ventures, Ascension Ventures and Echo Ventures.
The company intends to use the funds to expand its business reach.
Led by Chris Riopelle, CEO, Strive Health combines advanced technology with patient care to slow kidney disease progression, prevent unnecessary hospitalizations, and expand access to optimal renal replacement therapies such as home dialysis and transplants.
The company’s artificial intelligence (AI)-powered data science models predict disease progression as specially trained clinicians use this data to help patients slow disease progression and manage other avoidable health risks. If patients progress to kidney failure, Strive is equipped to coordinate transplants or flexible home dialysis.
The company has signed contracts to deliver its innovative solution to leading healthcare payors and providers, including Humana, Blue Cross and Blue Shield of North Carolina, SSM Health, Conviva Care Centers and more. Strive also has partnerships with hundreds of nephrology providers through new Medicare payment models and growth plans for the coming year.
